FOR IMMEDIATE RELEASE
July 24, 2020
Contact: Cassie Ann Kiggen
WASHINGTON, DC – The National Venture Capital Association (NVCA) today responded to President Trump’s executive order proposing an International Pricing Index, which would tie Medicare’s drug prices to those in other countries.
“The world is in the middle of a pandemic, and we are all rooting on healthcare innovators to create vaccines and treatments for COVID-19. This includes venture capital-backed companies that are at the leading edge of COVID-related research,” said Bobby Franklin, President & CEO of NVCA. “Medical innovation is a national treasure of the United States, and it is imperative that policymakers not put up roadblocks to those who are working to develop new medicine. NVCA is very concerned with President Trump’s announced executive order on the International Pricing Index. Now is the time to encourage scientists, doctors, and investors to reach for new heights; not to implement policy that may stymie new healthcare approaches.”
About National Venture Capital Association
The National Venture Capital Association (NVCA) empowers the next generation of American companies that will fuel the economy of tomorrow. As the voice of the US venture capital and startup community, NVCA advocates for public policy that supports the American entrepreneurial ecosystem. Serving the venture community as the preeminent trade association, NVCA arms the venture community for success, serving as the leading resource for venture capital data, practical education, peer-led initiatives, and networking. For more information about NVCA, please visit www.nvca.org.
Devin Miller2020-07-24 21:16:152020-07-24 21:16:15Trump’s Executive Order on Drug Pricing Could Stymie New Healthcare Solutions